Page last updated: 2024-10-16

methane and Crohn Disease

methane has been researched along with Crohn Disease in 3 studies

Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).

Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.

Research Excerpts

ExcerptRelevanceReference
" Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD."3.72Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003)
"Patients with Crohn's disease, ulcerative colitis, and pneumatosis cystoides intestinalis had significantly lower prevalences of methane excretion (13%, 15%, and 11% respectively)."1.27Methane excretion in man--a study of breath, flatus, and faeces. ( Brydon, WG; Eastwood, MA; McKay, LF, 1985)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvarez Dorta, D1
Chalopin, T1
Sivignon, A1
de Ruyck, J1
Dumych, TI1
Bilyy, RO1
Deniaud, D1
Barnich, N1
Bouckaert, J1
Gouin, SG1
Pimentel, M1
Mayer, AG1
Park, S1
Chow, EJ1
Hasan, A1
Kong, Y1
McKay, LF1
Eastwood, MA1
Brydon, WG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175]Phase 259 participants (Actual)Interventional2018-12-24Terminated (stopped due to Interim Futility Analysis)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Breath Methane Production Based on a Single-point Breath Methane Test

Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010

Interventionparticles per million (Mean)
SYN-010 21 mg-22.623
SYN-010 42 mg-4.785
Placebo-10.081

Change From Baseline in the Weekly Average Number of Completely Spontaneous Bowel Movements (CSBM) Compared to the 12-week Treatment Period

Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionWeekly average CSBMs (Least Squares Mean)
SYN-010 21 mg1.53
SYN-010 42 mg0.32
Placebo0.51

Mean Change From Baseline in the Area-under-the-curve (AUC) of Breath Methane Production, Based on the 120-minute Lactulose Breath Test.

Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

Interventionparticles per million * min (Mean)
SYN-010 21 mg-18.678
SYN-010 42 mg-20.137
Placebo-39.199

Proportion of Overall Abdominal Pain Intensity Responders During the 12-week Treatment Period

An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg4
SYN-010 42 mg4
Placebo7

Proportion of Overall Bloating Responders During the 12-week Treatment Period

An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg3
SYN-010 42 mg3
Placebo1

Proportion of Overall Responders During the 12-week Treatment Period

An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg1
SYN-010 42 mg2
Placebo6

Proportion of Overall Stool Frequency Responders During the 12-week Treatment Period

An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg4
SYN-010 42 mg6
Placebo9

Proportion of Patients Using Rescue Medication

Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg9
SYN-010 42 mg11
Placebo8

Proportion of Patients With Adequate Relief

Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010

InterventionParticipants (Count of Participants)
SYN-010 21 mg1
SYN-010 42 mg2
Placebo6

Other Studies

3 other studies available for methane and Crohn Disease

ArticleYear
Physiochemical Tuning of Potent Escherichia coli Anti-Adhesives by Microencapsulation and Methylene Homologation.
    ChemMedChem, 2017, 06-21, Volume: 12, Issue:12

    Topics: Adhesins, Escherichia coli; Anti-Bacterial Agents; Bacterial Adhesion; Capsules; Crohn Disease; Esch

2017
Methane production during lactulose breath test is associated with gastrointestinal disease presentation.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:1

    Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal

2003
Methane excretion in man--a study of breath, flatus, and faeces.
    Gut, 1985, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Breath Tests; Colitis, Ulcerative; Colon; Crohn Disease; Feces; Female; Gas

1985